AMRN

Amarin Corporation plc focuses on the research, development, and commercialization of treatments for cardiovascular disease (CVD). The company is known for its product VASCEPA® (icosapent ethyl), which is approved by multiple regulatory authorities for reducing the risk of CVD events. Amarin employs a direct sales model in the U.S. and utilizes indirect distribution strategies internationally through partnerships, covering nearly 100 markets worldwide. Its customer base includes patients, healthcare providers, and advocacy groups.